Canbridge Pharmaceuticals Inc. has issued a supplemental announcement regarding its audited financial results for the year ended December 31, 2024, as detailed in the 2024 Annual Report. The announcement clarifies that 534,375 Shares underlying RSUs vested during the reporting period, and the table on page 46 includes a correction, removing the irrelevant concept of "exercise" from the Post-IPO RSU Scheme. Additionally, the company provided further information on the write-off of its right of use assets related to its Boston, U.S. office and laboratory, which was vacated in the second half of 2024. Despite vacating the premises, the lease remained legally binding until February 28, 2025. As of December 31, 2024, the lease liabilities were recognized in the financial statements, in accordance with IFRS 16, as the lease obligations had not been legally extinguished by that date. The company assures that except for these disclosures, all other information in the 2024 Annual Report remains unchanged.